Skip to Content

Rivastigmine Teva

Active Substance: rivastigmine
Common Name: rivastigmine
ATC Code: N06DA03
Marketing Authorisation Holder: Teva Pharma B.V.
Active Substance: rivastigmine
Status: Withdrawn
Authorisation Date: 2009-04-17
Therapeutic Area: Dementia Parkinson Disease Alzheimer Disease
Pharmacotherapeutic Group: Anticholinesterases

Therapeutic Indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

The marketing authorisation for Rivastigmine Teva has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide